Published online before print May 29, 2008, doi: 10.1161/CIRCRESAHA.108.176057
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2008 American Heart Association, Inc.
Cellular Biology |
Angiogenic Function of Prostacyclin Biosynthesis in Human Endothelial Progenitor Cells
From the Department of Anesthesiology and Molecular Pharmacology and Experimental Therapeutics (T.H., L.V.d'U., C.-F.L., Z.S.K) and Department of Internal Medicine (T.L., H.-C.L.), Mayo Clinic College of Medicine, Rochester, Minn.
Correspondence to Zvonimir S. Katusic at Mayo Clinic, Joseph Building 4-184, 200 First St SW, Rochester, MN 55905. E-mail katusic.zvonimir{at}mayo.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The role of prostaglandin production in the control of regenerative function of endothelial progenitor cells (EPCs) has not been studied. We hypothesized that activation of cyclooxygenase (COX) enzymatic activity and the subsequent production of prostacyclin (PGI2) is an important mechanism responsible for the regenerative function of EPCs. In the present study, we detected high levels of COX-1 protein expression and PGI2 biosynthesis in human EPCs outgrown from blood mononuclear cells. Expression of COX-2 protein was almost undetectable under basal conditions but significantly elevated after treatment with tumor necrosis factor-
. Condition medium derived from EPCs hyperpolarized human coronary artery smooth muscle cells, similar to the effect of the PGI2 analog iloprost. The proliferation and in vitro tube formation by EPCs were inhibited by the COX inhibitor indomethacin or by genetic inactivation of COX-1 or PGI2 synthase with small interfering (si)RNA. Impaired tube formation and cell proliferation induced by inactivation of COX-1 were rescued by the treatment with iloprost or the selective peroxisome proliferator–activated receptor (PPAR)
agonist GW501516 but not by the selective PGI2 receptor agonist cicaprost. Downregulation of PPAR by siRNA also reduced angiogenic capacity of EPCs. Iloprost failed to reverse PPAR siRNA-induced impairment of angiogenesis. Furthermore, transfection of PGI2 synthase siRNA, COX-1 siRNA, or PPAR siRNA into EPCs decreased the capillary formation in vivo after transplantation of human EPCs into the nude mice. These results suggest that activation of COX-1/PGI2/PPAR pathway is an important mechanism underlying proangiogenic function of EPCs.
Key Words: adult stem cells • angiogenesis • prostaglandins • peroxisome proliferator–activated receptor • cyclooxygenase
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Evidence continues to accumulate on the existence of circulating endothelial progenitor cells (EPCs) capable of stimulating angiogenesis and repair of injured endothelium.1–11 However, the mechanisms underlying the reported therapeutic effects of EPCs are poorly understood, thus limiting successful translation of EPC-based therapies into the clinical arena. Arachidonic acid metabolism via cyclooxygenase (COX)-1 and/or COX-2 in mature endothelium is of major importance in cardiovascular homeostasis.12,13 Prostacyclin (PGI2) is a key vasoactive substance released from the endothelium after activation of COX(s) by chemical or physical stimuli.12,13 Most importantly, PGI2 is known to have a wide range of vasoprotective and therapeutic effects.14 Recently, it has been recognized that PGI2 also has stimulatory effects on angiogenesis.15–19 Despite the fact that a substantial amount of literature is available on functional and therapeutic significance of COX(s) and PGI2 in the vasculature, the role of arachidonic acid metabolism in the regenerative function of EPCs has not been examined. In the present study, we hypothesized that activation of COX isoforms and high production of PGI2 are important mechanisms responsible for the regenerative function of EPCs. We provide compelling evidence that the proangiogenic effects of human EPCs are in part dependent on the biosynthesis and release of PGI2, and subsequent activation of peroxisome proliferator–activated receptor (PPAR)
. |
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
An expanded Materials and Methods section is available in online data supplement at http://circres.ahajournals.org.
Isolation, Culturing, and Phenotyping of EPCs
The protocol for collection and use of human blood samples was approved by the Institutional Review Board at the Mayo Clinic. EPCs (late outgrowth) were outgrown 2 to 3 weeks after culturing of mononuclear cells isolated from the peripheral blood of 15 healthy male subjects (45±4 years old) as previously described.9 Both EPCs and human coronary artery endothelial cells (CAECs) (Clonetics; from 4 male donors [28±2 years old]) were cultured in endothelial growth medium-2 (EGM-2) (Clonetics). Human coronary artery smooth muscle cells (CSMCs) (Clonetics) were cultured in SmGM-2 SingleQuots (Clonetics). All experiments were performed using cells cultured from passages 4 to 8.
Morphological appearance and fluorescence-activated cell sorting were used to define endothelial cell phenotype of EPCs as previously described.1,9
NO Synthase Enzyme Activity
The total (including calcium-dependent and -independent) NO synthase (NOS) enzyme activity of EPCs and CAECs was determined by measuring L-citrulline synthesis from L-arginine, as previously described.20
Prostaglandins and Thromboxane Measurement
Subconfluent cells were incubated in EBM-2 (8 mL /100 mm dish) for 24 hours. The supernatant (conditioned medium [CM]) was collected and immediately mixed with 40 µL of 0.2 mol/L EDTA/PBS and stored at –80°C. Prostaglandin E2 (PGE2) and 6-keto prostaglandin F1 (6-keto PGF1) (the degradation product of PGI2), and thromboxane B2 (TXB2) (a breakdown product of TXA2) were assayed using EIA kits (Cayman Chemical Co21).
Western Blot Analysis
Western blotting was performed as previously described.22 Goat anti–COX-1, rabbit anti-PGI2 synthase (PGIS), rabbit anti-PPAR, and goat anti-actin antibodies were obtained from Santa Cruz Biotechnology. Rabbit anti–COX-2, PGH-PGE isomerase (PGEI), and TXA2 synthase (TXAS) antibodies were purchased from Cayman Chemical Co. Mouse anti-endothelial (e)NOS and rabbit anti–inducible NOS antibodies were purchased from BD Transduction Laboratory. Protein expression was normalized to actin.
Recording of Smooth Muscle Cell Membrane Potentials
Membrane potentials were recorded continuously at room temperature (22°C) on cultured CSMCs using patch clamp techniques as previously described.23
PGIS and COX-1 Knockdown by Small Interfering RNA
Small interfering (si)RNA against human PGIS, COX-1, or PPAR (PGIS siRNA, COX-1 siRNA, or PPAR siRNA, respectively), and control (Ct) siRNA were obtained from Santa Cruz Biotechnology. The target sequences are listed in the online data supplement. EPCs at 50% confluence were transfected with 30 nmol/L (optimized concentration) PGIS siRNA or COX-1 siRNA (using 30 nmol/ Ct siRNA as a control) or 100 nmol/L PPAR siRNA (using 100 nmol/L Ct siRNA as a control), by use of Lipofectamine 2000 (Invitrogen) in serum-free medium (EBM-2), according to the protocol of the manufacturer. Fresh EGM-2 was added 6.5 hours after transfection, and the cells were analyzed 48 hours after transfection.
In Vitro Tube Formation Assay
Endothelial tube formation was assessed using Matrigel assay (BD Biosciences) as described.9
Bromo-2'-Deoxyuridine Incorporation Assay
After EPCs were transfected with PGIS siRNA, COX-1 siRNA, PPAR siRNA, or Ct siRNA, they were subjected to bromo-2'-deoxyuridine (BrdU) incorporation assay.
Transplantation of EPCs and In Vivo Capillary Assay
All of the experimental protocols were approved by the Institutional Animal Care and Use Committee of the Mayo Clinic. EPCs were transfected with PGIS siRNA, COX-1 siRNA, PPAR siRNA, or Ct siRNA for 48 hours. Cells (5x105) were mixed with 200 µL Matrigel, 30 µL EGM-2, and 20 µL FCS and were then subcutaneously injected into the flanks of anesthetized 8 to 12 weeks old athymic nude mice (B6 Cg Foxn1, male; Jackson Laboratory [Bar Harbor, Maine]) (1 gel injection per side of flank, 2 gel injections per mouse). Two weeks later, mice were euthanized and the grafts were excised for histological evaluation.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were immunostained with mouse anti–human vascular endothelial growth factor receptor (VEGFR)-2, mouse anti-eNOS, or mouse IgG (as a control).
Statistical Analysis
Data are presented as means±SEM. Differences between mean values of multiple groups were analyzed using ANOVA followed by Tukey test (SigmaStat 2.03 for Windows). Comparison between 2 groups was made using Student t test. P<0.05 was considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Characterization of EPCs
Numerous studies on the morphological, functional, and biochemical characteristics of EPCs isolated from circulating blood established 2 distinct populations of cells: early EPCs and late EPCs (blood outgrowth EPCs).1,3–10 In the present study, we focused on blood outgrowth EPCs,7,9 which have been shown to accelerate angiogenesis and reendothelialization.3,5 Outgrown colonies appeared 2 weeks after culturing of mononuclear cells in EGM2 (Figure 1A). Confluent cells grew into a monolayer with cobblestone appearance (Figure 1B). Fluorescence-activated cell sorting analysis revealed that EPCs were positive for endothelial cell surface antigens (VEGFR-2, CD31, and VE-cadherin). However, they did not express the myelomonocytic cell marker CD14. Only a small portion of the population expressed the hematopoietic progenitor marker CD34 (Figure 1C).
|
Cultured EPCs had significantly lower total NOS enzymatic activity compared to CAECs (Figure 1D). The protein levels of eNOS were also significantly lower in EPCs (Figure 1E). Because tumor necrosis factor (TNF)- is among the major proinflammatory cytokines released during cellular infiltration after ischemia,24 we examined the eNOS expression in response to TNF-. Treatment with TNF- reduced eNOS expression in both EPCs and CAECs. The effect of TNF- was more pronounced in EPCs (Figure 1E), consistent with our previous report.9 Inducible NOS protein was undetectable in both cell types (data not shown).
Profile of Prostaglandin-Producing Enzymes and Production of Prostaglandins
In contrast to eNOS, Western blotting demonstrated that protein level of COX-1 was significantly higher in EPCs than in CAECs (Figure 2A). Moreover, the expression of TXAS protein was significantly lower in EPCs (Figure 2C), whereas CAECs and EPCs expressed similar levels of PGIS and PGEI proteins (Figure 2B and 2D). Under basal conditions, the expression of COX-2 was almost undetectable in both cell types (Figure 2E). TNF- treatment induced COX-2 expression in both EPCs and CAECs (Figure 2E) but did not change protein levels of COX-1, PGIS, TXAS, and PGEI (data not shown).
|
Strikingly, under basal conditions EPCs released a 4-fold higher amount of PGI2 (determined by measuring 6-keto PGF1) compared with that released from CAECs (Figure 3A). SC560 (0.1µmol/L, a selective COX-1 inhibitor) or COX-1 siRNA significantly reduced PGI2 production in EPCs (Figure 3E and 3F). The production of PGI2 in EPCs was significantly increased by treatment with TNF-. However, TNF- had only a mild stimulatory effect on PGI2 production in CAECs (Figure 3A). The productions of TXA2 (measured as TXB2) and PGE2 were not significantly different between these 2 cell types under basal conditions (Figure 3B and 3C). Treatment by TNF- increased TXA2 and PGE2 production in EPCs (Figure 3B and 3C). The ratio of PGI2/TXA2 was significantly higher in EPCs under basal conditions and in the presence of TNF- (Figure 3D).
|
Hyperpolarization of Human CSMCs by CM of EPCs
To determine biological activity of prostaglandins released by EPCs, we measured the effects of EPCs CM on the membrane potentials of human CSMCs. The membrane potential at baseline (EBM-2) was –40.8±2.9 mV (room temperature). CM obtained from CAECs produced a mild hyperpolarization of CSMCs (–43.1±3.5 mV). However, CM of EPCs produced a significantly stronger hyperpolarizing effect on CSMCs (–50.1±4.5 mV) (Figure 4B). Incubation of EPCs with COX inhibitor indomethacin abolished the effect of CM derived from EPCs on membrane potential (Figure 4), suggesting that these effects were mediated by the products of arachidonic acid metabolism via COX pathway. The hyperpolarization of CSMCs by CM of EPCs was blocked by 0.1 µmol/L iberiotoxin (a selective BK channel blocker; data not shown), suggesting that BK channels are involved in the hyperpolarization of the membrane potential. The effect of CM of EPCs was mimicked by 1 µmol/L iloprost (a stable PGI2 analog), which hyperpolarized membrane potential from –39.3±6.2 mV at baseline to –50.4±5.7 mV (n=3, P<0.05), demonstrating that activation of PGI2 receptors was indeed coupled with hyperpolarization. These results were consistent with previous observation that iloprost activated BK channel in rat CSMCs.25 Because PGI2 was the most abundant prostaglandin present in the CM of EPCs (Figure 3), our findings suggested that the hyperpolarizing effect of CM is most likely mediated by PGI2.
|
mV) after treatment with CMs derived from CAECs, EPCs, or EPCs+Indo is shown in the bar graph. Treatment with CM of EPCs significantly hyperpolarized the membrane potential by 9.29±1.95 mV, which was reversed in the presence of 10 µmol/L Indo (n=5 to 6). *P<0.05 compared with EBM-2, CM-CAECs, or CM-EPCs+Indo.
Cell Proliferation
In the next series of experiments, we examined the role of PGI2 in the regenerative function of EPCs. EPCs proliferation was inhibited by 10 µmol/L indomethacin (Figure 5A), and this effect was reversed by iloprost (3 µmol/L). COX-1 inhibitor SC560 (1 or 5 µmol/L) inhibited EPCs growth in a concentration-dependent manner, whereas the same concentrations of COX-2 inhibitor NS398 had no significant effect on EPCs proliferation (Figure 5B). Most importantly, PGIS siRNA or COX-1 siRNA also significantly decreased EPC growth and BrdU incorporation (Figure 6A through 6E). Iloprost rescued the decreased cell proliferation induced by PGIS siRNA or COX-1 siRNA (Figure 6C through 6F).
|
|
Because iloprost and PGI2 activate PGI2 receptor and PPARs,18,26,27 we further investigated the mechanisms of PGI2-dependent mitogenesis. It has been shown that PPAR mediates PGI2-induced angiogenesis28 and endothelial survival.18 Therefore, we examined the role of PPAR in the PGI2-mediated angiogenesis in EPCs. COX-1 siRNA transfected EPCs were treated with 3 µmol/L GW501516 (a selective PPAR agonist) or 1 µmol/L cicaprost (a selective PGI2 receptor agonist with almost no binding activity for PPARs26,27). GW501516 and iloprost rescued cell proliferation in EPCs transfected with COX-1 siRNA, whereas cicaprost did not have any effect (Figure 6D and 6F). In contrast, both cicaprost (1 µmol/L) and iloprost (3 µmol/L) significantly increased cAMP in the EPCs by 2.3±0.8- and 2.7±0.5-fold, respectively (data not shown), demonstrating a similar stimulating effect of these compounds on PGI2 receptor. Thus, these results point to an essential role of PPAR in the PGI2-dependent and iloprost-induced mitogenesis. Furthermore, downregulation of PPAR in EPCs by PPAR siRNA decreased cell proliferation (Figure 6G and 6H). The rescue effect of iloprost was abolished in the cells treated with PPAR siRNA (Figure 6H), thereby confirming that PPAR is the major PPAR isoform responsible for the mitogenic effect of PGI2 and iloprost.
In Vitro Angiogenesis
The in vitro tube formation by EPCs was reduced by indomethacin. This inhibitory effect was reversed by 1 µmol/L iloprost (Figure 7A and 7B). Genetic inactivation of PGIS and COX-1 by siRNA also significantly impaired the tube formation by EPCs (Figure 7C and 7D). Iloprost and GW501516, but not cicaprost, reduced the impairment of in vitro angiogenesis induced by COX-1 siRNA (Figure 7D). Furthermore, genetic inactivation of PPAR caused a decrease in the tube formation by EPCs, which was not reversed by iloprost or GW501516 (Figure 7E). These results indicated that angiogenic effect of PGI2 and iloprost is primarily mediated by activation of PPAR.
|
In Vivo Angiogenesis
To further examine the role of PGI2 in the angiogenic capacity of EPCs, we transplanted EPCs treated with COX-1 siRNA, PGIS siRNA, or Ct siRNA, into the nude mice. Two weeks later, capillaries positive for human VEGFR-2 were formed in the gel plugs, many of them containing red blood cells (Figure 8A through 8D). Transfection of PGIS siRNA or COX-1 siRNA significantly reduced the in vivo capillary formation in these preparations (Figure 8C through 8E). Downregulation of PPAR expression also impaired the in vivo angiogenesis (Figure 8F), supporting the concept that COX-1/PGI2/PPAR pathway in human EPCs plays an important role in angiogenesis.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The results of the present study demonstrate that the proangiogenic function of human EPCs is critically dependent on arachidonic acid metabolism and biosynthesis of PGI2. We report several novel findings: (1) EPCs release high levels of PGI2, and this is associated with intrinsically high levels of COX-1 expression; (2) production of TXA2 and PGE2 is low and similar between EPCs and CAECs; (3) the in vitro and in vivo angiogenic capacity of EPCs is dependent on the endogenous production of PGI2 in EPCs; (4) the PGI2-dependent angiogenic function of EPCs is mediated by activation of PPAR
rather than PGI2 receptor. These results suggest that COX-1/PGI2/PPAR is an important signaling pathway in the regenerative function of EPCs. In this study, we found a striking difference between PGI2 production in human EPCs and in human CAECs. Because biochemical and functional heterogeneity among human primary endothelial cells is well established, our results may not be generalized to include comparison between EPCs and endothelial cells from other vascular beds. Nonetheless, the study provides strong evidence that PGI2 is critical for the angiogenic function and vascular protection of EPCs. Previous studies have established that vasodilator effect of PGI2 is mediated in part by hyperpolarization of membrane potential in vascular smooth muscle cells.29,30 Because PGI2 was the most abundant product of arachidonic acid metabolism detected in our experiments, we examined the effect of CMs (obtained from both EPCs and CAECs) on membrane potential of smooth muscle cells. As anticipated, EPCs CM has strong hyperpolarizing properties, which are significantly greater than those of CAECs CM. Most notably, treatment of EPCs with indomethacin abolished the effect of CM on membrane potential, suggesting that activity of COX(s) is critical for the paracrine effect of EPCs on smooth muscle cells. Hyperpolarization of membrane potential is among the key mechanisms that produce smooth muscle relaxation. Our results thus suggest that EPCs may cause vasodilatation and increase local blood flow by paracrine-induced hyperpolarization.
Several lines of evidence suggest that under our experimental conditions, the majority of PGI2 was generated by activation of COX-1: (1) under basal conditions, EPCs expressed high levels of COX-1, whereas COX-2 protein was almost undetectable; (2) inhibition of COX-1 reduced EPCs proliferation, whereas COX-2 inhibitor did not affect cell proliferation; (3) the inhibitory effect of PGIS siRNA on angiogenic response was not statistically different from the inhibition of angiogenesis induced by siRNA designed to inactivate COX-1; and (4) production of PGI2 was significantly reduced by a COX-1 selective inhibitor, SC560, or COX-1 siRNA. However, we wish to point out that at the present time, the relative degree of COX-1/PGI2 pathway contribution (as compared with COX-2 or other paracrine mechanisms31) to angiogenic function of EPCs is difficult to determine. Based on our findings with selective pharmacological or genetic inhibition of COX-1 or PGIS, it appears likely that mechanisms other than COX-1/PGI2 pathway are also contributors to the ability of EPCs to stimulate angiogenesis.
There are 2 major signaling pathways responsible for the vascular effects of PGI2. The classic PGI2 signaling is mediated via a G protein–coupled cell membrane receptor, leading to an activation of adenylyl cyclase and an increase in cAMP.32,33 Stimulation of this pathway by PGI2 enhances mitogenic effects of growth factors (other than PGI2) or cross activation of RAS/RAF/MEK/ERK mitogenic pathway.33 PGI2 may also stimulate angiogenesis by activation of PPARs.18,28,32,34 PGI2 analogs have been shown to induce DNA binding and transcriptional activation by PPAR and PPAR.27 Recent studies suggest that activation of PPAR by PGI2 is responsible for regulation of angiogenesis and apoptosis in endothelial cells.18,27,28,34,35 The colocalization of COX/PGIS at the nuclear membrane is consistent with the ability of endogenous PGI2 to activate nuclear receptors.32 We also detected the perinuclear distribution of PGIS in EPCs (T.H. and Z.S.K., unpublished observation, 2006). In the present study, we found that the impairment of angiogenesis by inactivation of COX-1 was reversed by a selective agonist of PPAR, GW501516. This effect was similar to the effect of iloprost, suggesting that activation of PPAR is a major mechanism underlying the effect of iloprost. In contrast, cicaprost (a PGI2 analog that dose not activate PPAR) did not rescue the COX-1 siRNA phenotype, supporting the concept that PGI2 receptor plays a minor role in PGI2-induced angiogenesis. Furthermore, downregulation of PPAR also inhibited angiogenic function of EPCs. Iloprost failed to rescue the impairment of angiogenesis induced by PPAR siRNA, strongly suggesting that PPAR is the major mediator responsible for PGI2-dependent angiogenesis. GW501516 also failed to correct the inhibitory effect of PPAR siRNA, confirming the effectiveness of this siRNA. Most importantly, the results of in vivo experiments reinforced our conclusion that COX-1/PGI2/PPAR pathway is an important signaling mechanism in the angiogenic function of EPCs.
Interaction between transplanted human EPCs and endogenous mouse endothelium has not been fully characterized in our in vivo experiments. Two mechanisms may account for the reduced angiogenesis by genetically manipulated human EPCs, impaired angiogenic capacity of transplanted EPCs per se, and/or reduced ability of EPCs to stimulate angiogenic function of existing mouse endothelium. The present literature suggests that EPCs produce and release well established angiogenic molecules including VEGF,8 thereby supporting the concept that paracrine stimulation of existing endothelium is an important mechanism of EPC-induced angiogenesis. However, with regard to in vivo angiogenic effect of human EPCs, our results do not allow any conclusion regarding the relative contribution of transplanted EPCs per se, versus angiogenic stimulation of existing mouse endothelium by paracrine effects of EPCs.
TNF- is among the most important proinflammatory cytokines present in the ischemic tissues.24 TNF- treatment increases PGIS expression in bovine endothelial cells.36 In the present study, however, we did not detect the induction of PGIS by TNF- in human EPCs or human CAECs. The reason for this discrepancy between bovine and human endothelial cells is not immediately apparent but could be attributable to the species differences. Interestingly, TNF-–stimulated COX-2 expression in both EPCs and CAECs by a similar magnitude, however, TNF- had significantly more pronounced stimulatory effects on PGI2 production in EPCs. It is, therefore, likely that COX-2 activity is an important component of angiogenic activity of EPCs exposed to proinflammatory environment. The exact mechanisms underlying the high production of PGI2 in EPCs activated by TNF- are unclear but could be explained by an elevated expression of TNF- receptors, increased mobilization of arachidonic acid,37 or high antioxidant capacity of EPCs protecting PGIS from inactivation by peroxynitrite.9,38 Indeed, previous studies demonstrated that human EPCs had a high level of manganese superoxide dismutase expression9 and low intracellular concentration of reactive oxygen species.39 These findings coupled with detected low enzymatic activity of NOS suggest that EPCs may be able to minimize production of peroxynitrite, which is generated by a chemical reaction between superoxide anion and NO in ischemic tissue. This could enhance the ability of EPCs to robustly increase PGI2 production in response to TNF-, thus securing preservation of strong vascular protective and proangiogenic effects of EPCs under the conditions of oxidative stress.
This study is the first to demonstrate the importance of arachidonic acid metabolism and biosynthesis of PGI2 in the mediation of proangiogenic and vasodilator effect of human EPCs. The results provide a novel insight into the mechanism of PGI2-dependent angiogenesis in EPCs. Our observations suggest that adverse cardiovascular effects of COX(s) inhibitors may involve interference of these compounds with regenerative program of EPCs.
|
Acknowledgments |
|---|
Sources of Funding
This work was supported by the NIH grants HL-53524 and HL-66958 and by the Mayo Foundation.
Disclosures
None.
|
Footnotes |
|---|
Original received August 28, 2007; resubmission received March 20, 2008; revised resubmission received May 12, 2008; accepted May 16, 2008.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964–967.
2. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002; 106: 3009–3017.
3. Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY, Kim TY, Cho HJ, Kang HJ, Chae IH, Yang HK, Oh BH, Park YB, Kim HS. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation. 2005; 112: 1618–1627.
4. He T, Smith LA, Harrington S, Nath KA, Caplice NM, Katusic ZS. Transplantation of circulating endothelial progenitor cells restores endothelial function of denuded rabbit carotid arteries. Stroke. 2004; 35: 2378–2384.
5. Kong D, Melo LG, Mangi AA, Zhang L, Lopez-Ilasaca M, Perrella MA, Liew CC, Pratt RE, Dzau VJ. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation. 2004; 109: 1769–1775.
6. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003; 9: 702–712.[CrossRef][Medline] [Order article via Infotrieve]
7. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000; 105: 71–77.[Medline] [Order article via Infotrieve]
8. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, Park YB. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004; 24: 288–293.
9. He T, Peterson TE, Holmuhamedov EL, Terzic A, Caplice NM, Oberley LW, Katusic ZS. Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol. 2004; 24: 2021–2027.
10. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA. Re-defining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007; 109: 1801–1809.
11. Gulati R, Jevremovic D, Witt TA, Kleppe LS, Vile RG, Lerman A, Simari RD. Modulation of the vascular response to injury by autologous blood-derived outgrowth endothelial cells. Am J Physiol Heart Circ Physiol. 2004; 287: H512–H517.
12. Alfranca A, Iniguez MA, Fresno M, Redondo JM. Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc Res. 2006; 70: 446–456.
13. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006; 116: 4–15.[CrossRef][Medline] [Order article via Infotrieve]
14. Wu KK, Liou JY. Cellular and molecular biology of prostacyclin synthase. Biochem Biophys Res Commun. 2005; 338: 45–52.[CrossRef][Medline] [Order article via Infotrieve]
15. Buchanan FG, Chang W, Sheng H, Shao J, Morrow JD, DuBois RN. Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. Gastroenterology. 2004; 1275: 1391–1400.
16. Pichiule P, Chavez JC, LaManna JC. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem. 2004; 279: 12171–11280.
17. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation. 1998; 97: 99–107.
18. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor-{delta} mediated 14–3-3 upregulation. Arterioscler Thromb Vasc Biol. 2006; 26: 1481–1487.
19. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol. 2004; 31: 2–11.[Medline] [Order article via Infotrieve]
20. d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res. 2003; 92: 88–95.
21. Gurbel PA, Murugesan SR, Lowry DR, Serebruany VL. Plasma thromboxane and prostacyclin are linear related and increased in patients presenting with acute myocardial infarction. Prostaglandins Leukot Essent Fatty Acids. 1999; 61: 7–11.[CrossRef][Medline] [Order article via Infotrieve]
22. He T, Weintraub NL, Goswami PC, Chatterjee P, Flaherty DM, Domann FE, Oberley LW. Redox factor-1 contributes to the regulation of progression from G0/G1 to S by PDGF in vascular smooth muscle cells. Am J Physiol Heart Cir Physiol. 2003; 285: H804–H812.
23. Lu T, Katakam PV, VanRollins M, Weintraub NL, Spector AA, Lee HC. Dihydroxyeicosatrienoic acids are potent activators of Ca(2+)-activated K(+) channels in isolated rat coronary arterial myocytes. J Physiol. 2001; 534: 651–667.
24. Vandervelde S, van Luyn MJ, Tio RA, Harmsen MC. Signaling factors in stem cell-mediated repair of infarcted myocardium. J Mol Cell Cardiol. 2005; 39: 363–376.[CrossRef][Medline] [Order article via Infotrieve]
25. Lu T, Wang XL, He T, Zhou W, Kaduce TL, Katusic ZS, Spector AA, Lee HC. Impaired arachidonic acid-mediated activation of large-conductance Ca2+-activated K+ channels in coronary arterial smooth muscle cells in Zucker Diabetic Fatty rats. Diabetes. 2005; 54: 2155–2163.
26. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999; 79: 1193–1226.
27. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A. 1997; 94: 4312–4317.
28. Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM, Dey SK. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev. 1999; 13: 1561–1574.
29. Tanaka Y, Horinouchi T, Koike K. New insights into beta-adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation. Clin Exp Pharmacol Physiol. 2005; 32: 503–514.[Medline] [Order article via Infotrieve]
30. Tanaka Y, Koike K, Toro L. MaxiK channel roles in blood vessel relaxations induced by endothelium-derived relaxing factors and their molecular mechanisms. J Smooth Muscle Res. 2004; 40: 125–153.[CrossRef][Medline] [Order article via Infotrieve]
31. He T, Peterson TE, Katusic ZS. Paracrine mitogenic effect of human endothelial progenitor cells: role of interleukin-8. Am J Physiol Heart Circ Physiol. 2005; 289: H968–H972.
32. Lim H, Dey SK. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology. 2002; 143: 3207–3210.
33. Dumaz N, Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J. 2005; 272: 3491–3504.[CrossRef][Medline] [Order article via Infotrieve]
34. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D. Activation of PPAR{beta}/{delta} induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol. 2007; 27: 63–69.
35. Pola R, Gaetani E, Flex A, Aprahamian TR, Bosch-Marcé M, Losordo DW, Smith RC, Pola P. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol. 2004; 36: 363–370.[CrossRef][Medline] [Order article via Infotrieve]
36. Hara S, Miyata A, Yokoyama C, Inoue H, Brugger R, Lottspeich F, Ullrich V, Tanabe T. Isolation and molecular cloning of prostacyclin synthase from bovine endothelial cells. J Biol Chem. 1994; 269: 19897–19903.
37. Kronke M, Adam-Klages S. Role of caspases in TNF-mediated regulation of cPLA(2). FEBS Lett. 2002; 531: 18–22.[CrossRef][Medline] [Order article via Infotrieve]
38. Nie H, Wu JL, Zhang M, Xu J, Zou MH. Endothelial nitric oxide synthase-dependent tyrosine nitration of prostacyclin synthase in diabetes in vivo. Diabetes. 2006; 55: 3133–3141.
39. Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM, Dimmeler S. Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. Blood. 2004; 104: 3591–3597.
Related Article:
Circ. Res. 2008 103: 7-9.
This article has been cited by other articles:
 |
|
 |
|
  D. Strassheim, S. R. Riddle, D. L. Burke, M. W. Geraci, and K. R. Stenmark Prostacyclin Inhibits IFN-{gamma}-Stimulated Cytokine Expression by Reduced Recruitment of CBP/p300 to STAT1 in a SOCS-1-Independent Manner J. Immunol., December 1, 2009; 183(11): 6981 - 6988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Biscetti and R. Pola Endothelial Progenitor Cells and Angiogenesis Join the PPARty Circ. Res., July 3, 2008; 103(1): 7 - 9. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||